脂代谢与PD-1/PD-L1抑制剂疗效的研究进展  

Research progress in lipid metabolism and efficacy of PD-1/PD-L1 inhibitors

作　　者：陈宁 李桂香[1] Chen Ning;Li Gui-xiang(Cancer Center,The Second Hospital of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]兰州大学第二医院肿瘤中心,甘肃兰州730030

出　　处：《兰州大学学报（医学版）》2022年第7期87-90,共4页Journal of Lanzhou University（Medical Sciences）

摘　　要：脂代谢作为肿瘤微环境中一种常见的代谢改变,相关指标(脂肪酸、胆固醇)的变化可以影响免疫细胞的功能,进而影响肿瘤的免疫治疗,在预测程序性死亡受体-1/程序性死亡分子配体-1免疫抑制剂的疗效方面有潜在的重要临床价值。本综述研究脂代谢相关指标的变化在预测程序性死亡受体-1/程序性死亡分子配体-1免疫抑制剂疗效方面的进展,为临床免疫治疗提供一定的参考价值。Lipid metabolism is a common metabolic change in the tumor microenvironment. The changes in lipid metabolism-related indicators(fatty acids and cholesterol) can affect the function of immune cells and further affect the immunotherapy of tumors. It has a potential important clinical value in predicting the therapeutic effect of programmed death-1/programmed death ligand 1(PD-1/PD-L1) inhibitors. This paper reviewed the research progress in the changes of lipid metabolism related indexes in predicting the efficacy of PD-1/PD-L1 inhibitors, so as to provide some reference for clinical immunotherapy.

关 键 词：脂代谢 程序性死亡受体-1/程序性死亡分子配体-1抑制剂 疗效预测 

分 类 号：R589.2[医药卫生—内分泌]